Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | KYNU | Q16719 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27189305 | 0.91 | PPARA (0.51) | PPARACTSSCTSKPPARGSYK | |
| SCHEMBL4683881 | 0.88 | SYK (0.47) | PPARACTSSCTSKPPARGSYK | |
| SCHEMBL2574963 | 0.83 | CTSS (0.54) | PPARACTSSCTSKSYKATM | |
| SCHEMBL20439333 | 0.83 | CTSS (0.54) | PPARACTSSCTSKSYKATM | |
| SCHEMBL2574965 | 0.83 | CTSS (0.54) | PPARACTSSCTSKSYKATM | |
| SCHEMBL1095762 | 0.80 | CTSK (0.63) | CTSSCTSKKLK5ATMMEN1 | |
| SCHEMBL1951343 | 0.80 | CTSK (0.63) | CTSSCTSKKLK5ATMMEN1 | |
| SCHEMBL1095763 | 0.80 | CTSK (0.63) | CTSSCTSKKLK5ATMMEN1 | |
| SCHEMBL23837230 | 0.79 | CTSS (0.60) | PPARACTSSCTSKPPARGSYK | |
| SCHEMBL17724519 | 0.79 | CTSS (0.60) | PPARACTSSCTSKPPARGSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | PPARA 3280/4885CTSS 1293/4885CTSK 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.